| Rank |
Status |
Study |
| 1 |
Unknown †
|
Operational Research Management for Children With Severe Pneumonia
| Condition: |
Pneumonia |
| Interventions: |
Other: Amoxycilline, Cephradine followed by follow up on day 3; Other: Injectable ampicillin followed by urgent referral |
| Outcome Measures: |
Proportion of Severe Pneumonia cases approapriately treated as per the Modified IMCI guideline; Proportion of severe Pneumonia cases complied appropriately with followup advice given by the health care providers; Proportion of childhood Pneumonia cases treated by trained service provider |
|
| 2 |
Not yet recruiting
|
Safety, Tolerability, and Efficacy Study of Prophylactic Streptococcus Pneumoniae Vaccine Following Challenge With S. Pneumoniae
| Conditions: |
Pneumococcal Infections; Streptococcus Pneumoniae; Pneumonia, Pneumococcal |
| Interventions: |
Biological: GEN-004 with Aluminum Hydroxide Adjuvant; Biological: Placebo |
| Outcome Measures: |
Efficacy of GEN-003 as measured by reduction in nasopharyngeal colonization; Evaluation of the safety and tolerability of GEN-004 with aluminum hydroxide as measured by frequency and severity of Adverse Events; Evaluation of the duration of S. Pneumoniae colonization through 14 days after inoculation; Evaluation of the immunogenicity of GEN-004 with aluminum hydroxide, as measured by TH17 (IL-17) and IgG responses to the antigens. |
|
| 3 |
Unknown †
|
Use of TREM-1 Protein to Differentiate Viral and Bacterial Pneumonias in Intubated Children
| Conditions: |
Viral Pneumonia; Bacterial Pneumonia |
| Intervention: |
|
| Outcome Measures: |
TREM-1 level in the BAL fluid of patients with pure viral Pneumonia in comparison to patients with viral with co-existing bacterial Pneumonia; TREM-1 level in the BAL fluid of patients with pure bacterial Pneumonia and no Pneumonia; TREM-1 level in the serum of all 4 groups; Length of ventilator support, length of ICU and hospital stay |
|
| 4 |
Unknown †
|
Microbiology and Clinical Outcome of Pneumonia
| Condition: |
Pneumonia |
| Intervention: |
|
| Outcome Measure: |
Success/favorable clinical response after treatment for Pneumonia |
|
| 5 |
Unknown †
|
Zinc as Adjunct to Treatment of Pneumonia
| Condition: |
Pneumonia |
| Intervention: |
Dietary Supplement: Zinc sulphate |
| Outcome Measures: |
Time (hours) to resolution of clinical signs of Pneumonia; Time (hours) to resolution of clinical signs of Pneumonia by type of associated pathiogens ( bacterial/viral) |
|
| 6 |
Recruiting
|
Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine
| Condition: |
Community Acquired Pneumonia |
| Interventions: |
Behavioral: BPS; Behavioral: Guideline |
| Outcome Measures: |
Use of Antibiotics in Each Group; Treatment Failure in Each Group |
|
| 7 |
Not yet recruiting
|
The Effectiveness of Co-packaging With Zinc to Improve Treatment of Diarrhea and Pneumonia in Guatemala
| Conditions: |
Diarrhea.; Pneumonia. |
| Intervention: |
Behavioral: Co-packaging and counseling messages |
| Outcome Measures: |
Percentage of caregivers who administer zinc to child for at least 8 days.; Percentage of caregivers who report giving zinc to child for at least 8 days.; Improved Provision of Care for Treatment of Diarrhea and Pneumonia |
|
| 8 |
Unknown †
|
Prevention of Post-operative Pneumonia (POPP)
| Conditions: |
Post-operative Pneumonia; Lung Cancer; Esophageal Cancer |
| Intervention: |
Procedure: Intensive Brushing Regimen |
| Outcome Measures: |
Incidence of postoperative Pneumonia in the two groups: lung cancer resection patients and esophageal resection patients; Compliance with preoperative brushing and mouthwash protocol |
|
| 9 |
Recruiting
|
Surveillance of Hospitalised Pneumonia and Bacterial Meningitis in Tône District, Togo, 2010-2013
| Conditions: |
Pneumonia, Bacterial; Pneumonia, Viral; Meningitis, Bacterial |
| Intervention: |
|
| Outcome Measures: |
Incidence of pneumococcal Pneumonia requiring hospitalisation, confirmed by blood culture or PCR analysis of blood; Incidence of pneumococcal meningitis, confirmed by culture or PCR on cerebro-spinal fluid; Incidence of radiologically confirmed Pneumonia requiring hospitalisation; Incidence of suspected Pneumonia requiring hospitalisation with elevated C-reactive protein serum concentration (<40mg/l); Incidence of suspected Pneumonia requiring hospitalisation with reduced oxygen saturation (<90%); Incidence of Pneumonia of other bacterial or viral etiology requiring hospitalisation; Incidence of acute meningitis of other bacterial etiology |
|
| 10 |
Unknown †
|
Usefulness of Microbiological Tests in Community-Acquired Pneumonia
| Condition: |
Community-Acquired Pneumonia |
| Intervention: |
Procedure: empirical versus microbiological guided treatment |
| Outcome Measures: |
Clinical and economic consequences obtained with the antibiotic selection in basis to early mcrobiological results; Importance of polimicrobial etiology in community-acquired Pneumonia; Practice usefulness of urinary antigen detection tests in Pneumonia |
|
| 11 |
Unknown †
|
Flu Vaccine Against Childhood Pneumonia, Bangladesh
| Conditions: |
Pneumonia; Laboratory Confirmed Influenza |
| Intervention: |
Biological: Trivalent inactivated influenza vaccine |
| Outcome Measures: |
Clinical Pneumonia; Laboratory confirmed influenza infection; Indirect effects; Epidemiological and clinical characteristics of influenza infection; Effect on non-influenza viral and bacterial invasive disease; Immunogenicity; Adverse events associated with the vaccine |
|
| 12 |
Unknown †
|
Impact of a Multidimensional Intervention in Elderly Patients With Pneumonia
| Conditions: |
Community Acquired Pneumonia; Healthcare-Associated Pneumonia |
| Intervention: |
Other: Multidimensional intervention |
| Outcome Measures: |
Healthcare resources utilization (readmissions and consultations to hospital and emergency department).; Functional status; Institutionalization; Survival |
|
| 13 |
Not yet recruiting
|
Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia
| Condition: |
Nosocomial Pneumonia |
| Interventions: |
Drug: ceftolozane/tazobactam; Drug: Meropenem |
| Outcome Measures: |
All Cause Mortality; Clinical response rates of ceftolozane/tazobactam versus meropenem in adult subjects with VNP.; Clinical response rates at the Late Follow-up (LFU) visit for ceftolozane/tazobactam versus meropenem in adult subjects with VNP.; Per-pathogen microbiological response rates of ceftolozane/tazobactam versus meropenem at TOC.; Microbiological response rates of ceftolozane/tazobactam versus meropenem at EOT; Clinical response rates at the TOC visit (ceftolozane/tazobactam versus meropenem) in the subset of subjects who had P. aeruginosa from the baseline lower respiratory tract culture; Day 14 all-cause mortality rates of subjects in the ceftolozane/tazobactam versus meropenem arms; Safety will be evaluated in the safety population by presenting summaries of deaths, AEs, laboratory evaluations, vital signs and physical exam in the 2 treatment groups; Pharmacokinetic parameters, such as maximum concentration achieved (Cmax), total exposure during one dosing interval (AUC0-τ), steady-state volume of distribution (Vss) and Clearance (CLss); Day 28 all-cause mortality rates of subjects in the ceftolozane/tazobactam versus meropenem arms in the Microbiological Intent-to-Treat (mITT) population; Clinical response rates at the TOC visit (ceftolozane/tazobactam versus meropenem) in the subset of subjects who had Enterobacteriaceae isolated from the baseline lower respiratory tract culture; Per-pathogen clinical response at TOC by baseline minimum inhibitory concentration (MIC) and Kirby-Bauer zone diameter for ceftolozane/tazobactam versus meropenem |
|
| 14 |
Unknown †
|
Ventilator Associated Pneumonia in Taper Guard Versus Normal Tube in ICU Patients
| Condition: |
Ventilator Associated Pneumonia |
| Interventions: |
Device: Taper Guard Endotracheal Tube; Other: Conventional endotracheal tube |
| Outcome Measures: |
incidence of ventilator associated Pneumonia(VAP); Number of days on the ventilator by the time patient is discharged from ICU or hospital or at time of death; The total number of days spent in the intensive care unit by the time of discharge from hospital or death; The number of days spent in the hospital by the time of discharge or death; number of deaths in each arm |
|
| 15 |
Recruiting
|
A Randomized Controlled Trial of Lung Ultrasound Compared to Chest X-ray for Diagnosing Pneumonia in the Emergency Department
| Condition: |
Pneumonia |
| Interventions: |
Other: Lung Ultrasound; Radiation: Chest X-Ray |
| Outcome Measures: |
Overall reduction of CXR needed to diagnose Pneumonia; Comparison of unscheduled healthcare visits after the index Emergency Department visit between those subjects who undergo CXR first and those who undergo LUS first.; Evaluation of the rate of antibiotic use between the two groups.; Comparison of the admission rates.; Comparison of the length of stay in the Emergency Department between the two groups. |
|
| 16 |
Recruiting
|
Effect of Atorvastatin on the Frequency of Ventilator-associated Pneumonia in Patients With Ischemic Stroke
| Conditions: |
Ventilator-associated Pneumonia; Ischemic Stroke |
| Interventions: |
Drug: Atorvastatin; Drug: Placebo |
| Outcome Measures: |
Cumulative frequency of ventilator-associated Pneumonia; Mortality; Ventilation free days; Antibiotic free days; Whether the bacteria of multidrug-resistance can be isolated from the sputum culture; Adverse effects |
|
| 17 |
Recruiting
|
Duration of Antibiotic Therapy in Community - Acquired Pneumonia
| Conditions: |
Pneumonia; BronchoPneumonia; PleuroPneumonia; Pneumonia, Bacterial; Pneumonia, Viral |
| Intervention: |
Other: Discontinuation of antibiotic therapy |
| Outcome Measures: |
Composite outcome including adverse events; Composite outcome of other adverse events; Antibiotic exposure; Adverse effects; Composite outcome of other adverse events at 90 days; Length of hospitalization; Costs |
|
| 18 |
Unknown †
|
Effectiveness of H1N1 Influenza Vaccines in Manitoba, Canada
| Conditions: |
Influenza; Pneumonia |
| Intervention: |
|
| Outcome Measures: |
Hospitalization with laboratory-confirmed influenza or Pneumonia; Hospitalization with influenza or Pneumonia |
|
| 19 |
Recruiting
|
Optimizing Dosing Regimen of Piperacillin/Tazobactam for Nosocomial Pneumonia
| Condition: |
Nosocomial Pneumonia |
| Interventions: |
Drug: C Group; Drug: E Group |
| Outcome Measures: |
Extension of the Piperacillin / tazobactam infusion time effect evaluation; Reducing antibiotic resistance |
|
| 20 |
Recruiting
|
Pharmacokinetics of Moxifloxacin in Patients With Pneumonia
| Condition: |
Pneumonia |
| Intervention: |
|
| Outcome Measure: |
The concentration of Moxifloxacin in blood-plasma |
|
